Transforming growth factor-β in renal disease

Kidney and Blood Pressure Research

Volumn 21, Issue 1, 1998, Pages 1-12

  Bitzer, Markus ^a   Sterzel, R Bernd ^a   Böttinger, Erwin P ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Animal models; Fibrosis; Gene targeting; Inflammation; Kidney; Transforming growth factor ; Transgenic mice

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; GENE TARGETING; GENETIC ENGINEERING; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; KIDNEY DISEASES; MICE; MICE, TRANSGENIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031747013     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025837     Document Type: Review

References (140)

1. Roberts AB, Sporn MB The transforming growth factors-β; in Sporn MB, Roberts AB (eds) Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors. Berlin, Springer, 1990, pp 419-472
2. Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597-641
3. Derynck R TGF-beta-receptor-mediated signaling Trends Biochem Sci 1994,19:548-553.
4. Kingsley DM The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8:133-146.
5. Daopin S, Piez KA, Ogawa Y, Davies DR: Crystal structure of transforming growth factor-beta 2: An unusual fold for the superfamily (see comments) Science 1992,257:369-373
6. Schlunegger MP, Grutter MG: Refined crystal structure of human transforming growth factor beta 2 at 1.95 A resolution. J Mol Biol 1993; 231:445-458.
7. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanic insights. Cell 1990;63.245-247.
8. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9.
9. Akhurst RJ, Fitzpatrick DR, Fowlis DJ, Gatherer D, Millan FA, Slager H: The role of TGF-beta's in mammalian development and neoplasia. Mol Reprod Dev 1992;32:127-135
10. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH: Transforming growth factor type beta Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171
11. McCartney-Francis NL, Wahl SM Transforming growth factor beta. A matter of life and death. J Leukoc Biol 1994,55:401-409.
12. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991,88:2918-2921.
13. Racke MK, Sriram S, Carlino J, Cannella B, Rame CS, McFarlin DE: Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-Beta 2. J Neuroimmunol 1993;46:175-183.
14. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292
15. Nathan C, Sporn M: Cytokines in context. J Cell Biol 1991;113:5:981-986.
16. Barcellos-Hoff MH: Latency and activation in the control of TGF-β. J Mam Grand Biol Neoplasia 1996;1:351-361.
17. Massague J: TGF-β signaling: Receptors, transducers and Mad proteins. Cell 1996;85:947-950.
18. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death Proc Natl Acad Sci USA 1993;90:770-774.
19. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschmann T: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359: 693-699.
20. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MWJ, Doetschman T: Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet 1995;11 409-414.
21. Kaartmen V, Voncken JW, Shuler C, Warburton D, Bu D, Heitserkamp N, Groffen J. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction Nature Genet 1995,11: 415-421.
22. Sanford LP, Ormsby I, Gittenberger-deGroot A, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T: TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-β knockout phenotypes. Development 1997,124:2659-2670.
23. Wang XJ, Greenhalgh DA, Bickenbach JR, Jiang A, Bundman DS, Krieg T, Derynck R, Roop DR: Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition. Proc Natl Acad Sci USA 1997;94:2386-2391.
24. Böttinger EP, Jakubczak JL, Roberts ISD, Mumy M, Hcmmati P, Bagnall K, Merlino G, Wakefield LM: Expression of a dominant negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas EMBO J 1997;16.2621-2633.
25. Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM: Transgenic mice over-expressing a dominant negative mutant type II TGF-β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997;57:5564-5570.
26. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92.2572-2576.
27. Roberts AB, Sporn MB: Differential expression of the TGF-beta isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol Reprod Dev 1992;32:91-98.
28. Erickson HP: Gene knockouts of c-src, transforming growth factor beta 1, and tenascin suggest superfluous, nonfunctional expression of proteins. J Cell Biol 1993;120:1079-1081.
29. Hines KL, Kulkarni AB, McCarthy JB, Tian H, Ward JM, Chrits M, McCartney-Francis NL, Furcht LT, Karlsson S, Wahl SM Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci USA 1994; 91:5187-5191.
30. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T: Early-onset multifocal inflammation in the transforming growth factor β-1 null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995;92:12215-12219.
31. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE: Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 1993;90:4577-4581.
32. Gamble JR, Khew-Goodall Y, Vadas MA: Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993;150:4494-4503.
33. Lefer AM, Ma XL, Weyrich AS, Scalia R: Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 1993;90:1018-1022
34. Dang H, Geiser AG, Letteno JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β1 knockout mice. J Immunol 1995;155:3205-3212.
35. Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB: Transforming growth factor beta 1 (TGF-beta 1) controls expression of major hitsocompatibility genes in the postnatal mouse: Aberrant hitsocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci USA 1993;90:9944-9948.
36. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, Roberts AB: Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 1996;98:2109-2119.
37. Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Campbell AJ, Lucia MS, Sporn MB, Roberts AB: Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse J Exp Med 1996;183:2337-2342.
38. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray Science 1995;270:467-470.
39. Bonyadi M, Rusholme SA, Cousins FM, Su HC, Biron CA, Farrall M, Akhurst RJ: Mapping of a major genetic modifier of embryonic lethality in TGF-beta 1 knockout mice. Nat Genet 1997;15:207-211.
40. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: Maternal rescue of transforming growth factor-beta 1 null mice. Science 1994;264:1936-1938
41. Wakefield LM, Letterio JJ, Chen T, Danielpour D, Allison RSH, Pai LH, Denicoff AM, Noone MH, Cowan KH, O'Shaughnessy JA, Sporn MB: Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995;1:129-136.
42. Luo G, Hofmann C, Bronckers LJJ, Sohocki M, Bradley A, Karsenty G BMP-7 is and inducer of nephrogenesis, and is required for eye development and skeletal patterning Genes Dev 1995;9.2808-2820.
43. Dudley AT, Lyons KM, Robertson EJ: A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 1995;9:2795-2807.
44. Ozkaynak E, Schnegelsberg PN, Oppermann H: Murine osteogenic protein (OP-1): High levels of mRNA in kidney, Biochem Biophys Res Commun 1991;179.116-123.
45. Oshima M, Oshima H, Taketo MM: TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis Dev Biol 1996,179 297-302.
46. Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, Moses HL: Expression of a truncated kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997;139:541-552.
47. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS: Transgenic mice with increased levels of TGF-β1 develop progressive renal disease Lab Invest 1996;74:991-1003.
48. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL: Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328: 1592-1598.
49. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J: Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 1995;1:282-284.
50. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995;1:74-79.
51. Dickson K, Philip A, Warshawsky H, O'Conner-McCourt M, Bergeron JJ: Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest 1995;5: 2539-2554.
52. Lin HY, Mustakas A: TGF-beta receptors: Structure and function. Cell Mol Biol 1994;40: 337-349.
53. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Call 1991,67:785-795.
54. Lopez-Casillas F, Wrana JL, Massague J: Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993,73:1435-1444
55. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA: Expression cloning and characterization of the TGF-β type III receptor. Cell 1991;67:797-805.
56. Lopez-Casillas F, Payne HM, Andres JL, Massague J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-568.
57. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992;267:19027-19030.
58. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C: Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 133:1109-1121
59. Massague J: Receptors for the TGF-beta family. Cell 1992;69:1067-1070.
60. O'Connor-McCourt MD, Wakefield LM: Latent transforming growth factor-beta in serum. A specific complex with alpha-2-macroglobulin. J Biol Chem 1987,262:14090-14099.
61. Danielpour D, Sporn MB: Differential inhibition of transforming growth factor beta-1 and beta-2 activity by alpha-2-macroglobulin J Biol Chem 1990;265:6973-6977
62. Burmester JK, Qian SW, Roberts AB, Huang A, Amatayakul-Chantler S, Suardet L, Odartchenko N, Madri JA, Sporn MB: Characterization of distinct functional domains of transforming growth factor beta. Proc Natl Acad Sci USA 1993;90:8628-8632.
63. Ruoslahti E, Yamaguchi Y, Hildebrand A, Border WA: Extracellular matrix/growth factor interactions Cold Spring Harb Symp Quant Biol 1992,57:309-315
64. Stach RM, Rowley DA: A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens. J Exp Med 1993;178.841-852.
65. Rowley DA, Becken ET, Stach RM: Autoantibodies produced spontaneously by young 1pr mice carry transforming growth factor beta and suppress cytotoxic T lymphocyte responses. J Exp Med 1995;181.1875-1880.
66. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG: Differential expression of transforming growth factor-β isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996;50:116-124.
67. Sharma K, Jin Y, Guo J, Ziyadch FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996,45: 522-530.
68. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephopathy. Kidney Int 1994,45:525-536.
69. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular diseae. Kidney Int 1986;29:502-510.
70. Wells RG, Yankelev H, Lin HY, Lodish HF: Biosynthesis of the type I and type II TGF-beta receptors. Implications for complex formation J Biol Chem 1997;272:11444-11451.
71. Hents YI., Moustakas A, Lin HY, Lodish HF: The types II and III transforming growth factor-beta receptors form homo-oligomers J Cell Biol 1994;126:139-154.
72. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF: Type I receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 1996;148:549-558
73. Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996,1:93-102.
74. El Nahas AM: Glomerulosclerosis: Intrinsic and extrinsic pathways Nephrol Dial Transplant 1996;11:773-777.
75. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453-462
76. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346: 371-374.
77. Border WA, Noble NA, Yamamoto T, Harper JR, Yu Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor βeta protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
78. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45 916-927.
79. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit Am J Pathol 1991,138:223-234.
80. Moll S, Menoud PA, Fulpius T, Pastore Y, Takahashi S, Fossati L, Vassalli JD, Sappino AP, Schifferli JA, Izui S: Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. Kidney Int 1995;48 1459-1468.
81. Hamaguchi A, Kim S, Ohta K, Yagi K, Yukimura T, Miura K, Fukuda T, Iwao H: Transforming growth factor-β1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension 1995;26:199-207
82. Cheng QL, Orikasa M, Morioka T, Kawachi H, Chen XM, Oite T, Shimizu F. Progressive renal lesions induced by adminitsration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Clin Exp Immunol 1995;102:181-185
83. He C, Zalups RK, Henderson DA, Striker GE, Striker LJ: Molecular analysis of spontaneous glomerulosclerosis in Os/+ mice, a model with reduced nephron mass. Am J Physiol 1995;269: F266-F273.
84. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993,92 2597-2601.
85. Ziyadeh FN, Han DC Involvement of transforming growth factor-β and its receptors in the pathogenesis of diabetic nephropathy Kidney Int 1997;52(suppl 60):7-11.
86. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994;267:F1094-F1001.
87. Shankland SJ, Scholey JW, Ly H, Thai K: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy Kidney Int 1994;46.430-442.
88. Abboud HE: Growth factors and diabetic nephropathy: An overview. Kidney Int 1997; 52(suppl 60).3-6.
89. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-β1 in patients with type II diabetes mellitus Diabetes 1997;46. 854-859.
90. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC: Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am J Physiol 1994; 266:F926-F933.
91. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonits ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
92. Pigmentel JLJr, Sundell CL, Wang S, Kopp JB, Montero J, Martinez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy Kidney Int 1995;48:1233-1246.
93. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor-β and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154-163.
94. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth factor-β isoforms in human glomerular disease, Kidney Int 1996;49. 461-469.
95. Pankewyez OG, Miao L, Isaacs R, Guan J, Pruett T, Haussmann G: Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity. Kidney Int 1996;50:1634-1640.
96. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism Proc Natl Acad Sci USA 1995,92:5545-5549.
97. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, Johnson RJ: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27kipl. Kidney Int 1997;51:1088-1089.
98. Schöcklmann HO, Rupprecht HD, Zauner I, Sterzel RB: TGF-beta 1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kidney Int 1997; 51.1228-1236.
99. Sütö ST, Fine LG, Shimizu F, Kitamura M In vivo transfer of engineered macrophages into the glomerulus. Endogenous TGF-β-mediated defense against macrophage-induced glomerular cell activation. J Immunol 1997;159: 2476-2483.
100. Miyazono K, Hellman U, Wernstedt C, Heldin CH: Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988;263:6407-6415
101. Gleizes PE, Beavis RC, Mazzieri R, Shen B, Rifkin DB Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-β binding protein-1 that mediates bonding to the latent transforming growth factor-β1. J Biol Chem 1996,271: 29891-29896.
102. Sharinen J, Taipale J, Keski-Oja J: Association for the small latent transforming growth factor-β with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 1996;15:245-253
103. Taipale J, Miyazono K, Heldin CH, Keski-Oja J: Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994;124:171-181.
104. Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factor-β binding protein domains involved in activation and transglutammase-dependent cross-linking of latent transforming growth factor-β J Cell Biol 1997,136:1151-1163
105. Harpel JG, Metz CN, Kojima S, Rifkin DB: Control of transforming growth factor-beta activity: Latency vs. activation Prog Growth Factor Res 1992;4.321-335
106. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J: Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung J Clin Invest 1997;100:768-776.
107. Miyazono K, Heldin CH: Latent forms of TGF-beta Molecular structure and mechanisms of activation. Ciba Found Symp 1991, 157:81-89.
108. Flaumenhaft R, Kojima S, Abe M, Rifkin DB: Activation of latent transforming growth factor beta. Adv Pharmacol 1993,24:51-76.
109. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE: Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1994;269: 26775-26782.
110. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 1995;270:7304-7310.
111. Marinides GN, Suchard SJ, Mookerjee BK: Role of thrombospondin in mesangial cell growth: Possible exitsence of an autocrine feedback growth circuit. Kidney Int 1994;46: 350-357.
112. Bugge TH, Flick MJ, Daugherty CC, Degen JL: Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9: 794-807.
113. Polverini PJ, DiPietro LA, Dixit VM, Hynes RO, Lawler J: Thrombospondin 1 knock out mice show delayed organization and prolonged neovacularization of skin wounds (abstract 1578). FASEB J 1995
114. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJS, Degen JL: Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996;87: 709-719.
115. Barcellos-Hoff MH, Ehrhart EJ, Kalia M, Jirtle R, Flanders K, Tsang MLS. Immunohitsochemical detection of active transforming growth factor-β in situ using engineered tissue. Am J Pathol 1995;147:1228-1237.
116. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein[a] mice. Nature 1994;370: 460-462.
117. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346 371-374.
118. Border WA, Noble NA, Yamamoto T, Harper JR, Yu Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
119. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, Ueda N, Imai E: Inhibition of TGF-β 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-155.
120. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329 1456-1462.
121. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zuchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med 1996;334:939-945.
122. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993,92:1366-1372.
123. 123; Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93.2431-2437.
124. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461
125. Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, Luzzana E, Colosio V, Bertani T, Remuzzi G: The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephrophathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonits. Am J Kidney Dis 1997,29:254-264.
126. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 1994,46.1346-1358.
127. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE Transforming growth factor beta I and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 1997;51:1553-1567.
128. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonits ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47.1285-1294.
129. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero J, Martinez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int 1995;48:1233-1246.
130. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S: Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994,45: 1637-1647.
131. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-673.
132. Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455-466.
133. Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, Ichiki T, Naftilan AJ, Fogo A, Inagami T: Tene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995;96:2947-2954.
134. Eddy AA. Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome. Am J Physiol 1994;266:F884-F893.
135. Nakayama M, Okuda S, Tamaki K, Fujishima M. Short- or long-term effects of a low-protein diet on fibronectin and transforming growth factor-beta synthesis in Adriamycin-induced nephropathy. J Lab Clin Med 1996;127.29-39.
136. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-βeta 1 knock out mice Development 1995;121.1845-1854.
137. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH: Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993,90:6076-6080.
138. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G: BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995;9:2808-2820.
139. Hofmann C, Luo G, Balling R, Karsenty G: Analysis of limb patterning in BMP-7 deficient mice. Dev Genet 1996;19:43-50.
140. Lee MS, Gu D, Feng L, Curriden S, Arnush M, Krahl T, Gurushanthaiah D, Wilson C, Loskutoff DL, Fox H, Savetnick N: Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am J Pathol 1995;147:42-52.